A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.

摘要: The incidence of breast cancer increases with age. This trial evaluated the efficacy and safety oral UFT (ftorafur plus uracil) leucovorin in elderly patients advanced cancer. Eligibility criteria included age > or =65 years, locally metastatic cancer, =70 years old). Protocol treatment was discontinued 2 (ages 78 83) secondary to severe gastrointestinal toxicity. One patient achieved a partial response. Although UFT/leucovorin had 1 patient, toxicity over 70 increased. Careful evaluation anticancer drug very is important as our population ages.